INCB018424 in Patients With Advanced Hematologic Malignancies
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00674479|
Recruitment Status : Completed
First Posted : May 7, 2008
Last Update Posted : March 29, 2017
|Condition or disease||Intervention/treatment||Phase|
|Acute Myeloid Leukemia Acute Lymphocytic Leukemia Myelodysplastic Syndrome Chronic Myelogenous Leukemia||Drug: INCB018424||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||56 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of INCB018424 in Patients With Advanced Hematologic Malignancies|
|Actual Study Start Date :||May 12, 2008|
|Actual Primary Completion Date :||March 23, 2017|
|Actual Study Completion Date :||March 23, 2017|
The starting dose of INCB018424 will be 25 mg by mouth twice daily.
Starting dose: 25 mg by mouth (po) twice daily for 7 days each week for 4 weeks.
- Response Rate [ Time Frame: Patients will be evaluated after each full cycle of therapy (28 days) for response. ]Survival, time to progression, time to treatment failure, and duration of response will be presented using Kaplan-Meier curves for each patient group. "Time of Response " defined as the period of time from the date of first study drug administration until the first objective documentation of response.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00674479
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Farhad Ravandi-Kashani, M.D.||M.D. Anderson Cancer Center|